PsychPGx Lab Publications
Select Publications
Bousman CA*, Stevenson J*, Ramsey L, Sangkuhl K, Hicks J, Strawn J, Singh A, Ruano G, Mueller D, Tsermpini E, Brown J, Bell G, Leeder JS, Gaedigk A, Scott S, Klein T, Caudle K, Bishop J (2023). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitors. Clinical Pharmacology & Therapeutics
Bousman CA, Maruf AA, Marques DF, Brown LC, Mueller DJ. (2023). Emergence, implementation, and future growth of pharmacogenomics in psychiatry: A narrative review. Psychological Medicine, 53, 7983-7993.
Vaziri N, Marques D, Greenway S, Bousman CA. (2023). The cellular mechanism of antipsychotic-induced myocarditis: A systematic review. Schizophrenia Research.
Forbes M, Hopwood M, Bousman CA. (2023). CYP2D6 and CYP2C19 variant coverage of commercial antidepressant pharmacogenomic testing panels available in Victoria, Australia. Genes, 14 (1945).
Turner A, Nofziger C, Ramey B, Ly R, Bousman CA, Agundez J, Sangkuhl K, Whirl-Carrillo M, Vanoni S, Dunnenberger H, Ruano G, Kennedy M, Phillips M, Hachad H, Klein T, Moyer A, Gaedigk A. (2023). PharmVar Tutorial on CYP2D6 Structural Variation Testing and Recommendations on Reporting. Clinical Pharmacology & Therapeutics.
Brown LC, Bobo WC, Gall CA, Muller DJ, Bousman CA. (2023). Pharmacomicrobiomics of antidepressants in depression: A systematic review. Journal of Personalized Medicine, 13(7): 1086.
Jessel CD, Narang A, Zuberi R, Bousman CA. (2023). Sleep quality and duration in children that consume caffeine: Impact of dose and genetic variation in ADORA2A and CYP1A. Genes, 14(2): 289.
Brown LC, Stanton JD, Bharthi K, Maruf AA, Mueller DJ, Bousman CA. (2022). Pharmacogenomic testing and depressive symptom remission: A systematic review and meta-analysis of prospective, controlled clinical trials. Clinical Pharmacology & Therapeutics.
Hayashi M, Bousman CA. (2022). Experience, knowledge, and perceptions of pharmacogenomics among healthcare professionals in Alberta hospitals. Pharmacy.
Vaziri N, Marques D, Wang X, Machiraju P, Narang A, Vlahos K, Pantelis C, Greenway SC, Bousman CA. (2022). Generation of two human induced pluripotent stem cell lines from peripheral blood mononuclear cells of clozapine-tolerant and clozapine-induced myocarditis patients with treatment-resistant schizophrenia. Stem Cell Research.
Maruf AA, Bousman CA. (2022). Approaches and hurdles of implementing pharmacogenetic testing in the psychiatric clinic. Psychiatry and Clinical Neuroscience Reports, 1(2), e26.
Narang A, Lacaze P, Ronaldson KJ, McNeil JJ, Jayaram M, Thomas N, Sellmer R, Crockford DN, Stowe R, Greenway SC, Pantelis C, Bousman CA. (2022). Whole-genome sequencing analysis of clozapine-induced myocarditis. The Pharmacogenomics Journal.
Stein K, Maruf AA, Müller DJ, Bishop, J.R.; Bousman CA. (2022). Serotonin Transporter Genetic Variation and Antidepressant Response and Tolerability: A Systematic Review and Meta-Analysis. Journal of Personalized Medicine.
Bousman CA, Mukerjee G, Men X, Dorfman R, Muller DJ, Thomas RE. (2021). Encountering Pharmacogenetic Testing Results in the Psychiatric Clinic. The Canadian Journal of Psychiatry.
Richardson N, Greenway SC, Bousman CA. (2021). Clozapine-induced myocarditis and patient outcomes after drug rechallenge following myocarditis: A systematic case review. Psychiatry Research.
Bousman CA, Oomen A, Jessel CD, Tampi RR, Forester BP, Eyre HA, Lavretsky H, Mueller DJ. (2021). Perspectives on the clinical use of pharmacogenetic testing in late-life mental healthcare: A survey of the American Association of Geriatric Psychiatry membership. American Journal of Geriatric Psychiatry.
Ahmed Z, Hao S, Williamson T, McMorris CA, Bousman CA. (2021). Psychotropic prescribing rates and pharmacogenomic testing implications for autism in the Canadian Primary Care Sentinel Surveillance Network. Pharmacogenetics and Genomics.
Bousman CA, Wu P, Aitchison KJ, Cheng T. (2021). Sequence2Script: A web-based tool for translation of pharmacogenetic data into evidence-based prescribing recommendations. Frontiers in Pharmacology
Bousman CA, Bengesser SA, Aitchison KJ, Amare AT, Aschauer H, Baune BT, Behroozi Asl B, Bishop JR, Burmeister M, Chaumette B, Chen L, Cordner ZA, Deckert J, Degenhardt F, DeLisi LE, Folkersen L, Kennedy JL, Klein TE, McClay JL, McMahon FJ, Musil R, Saccone NL, Sangkuhl K, Stowe RM, Tan EC, Tiwari AK, Zai CC, Zai G, Zhang J, Gaedigk A, Muller DJ. (2021). Review and Consensus on Pharmacogenomic Testing in Psychiatry. Pharmacopsychiatry, 54:5-17.
Maruf AA, Stein K, Arnold P, Aitchison K, Mueller DJ, Bousman CA. (2021). CYP2D6 and Antipsychotic Treatment Outcomes in Children and Youth: A Systematic Review. Journal of Child and Adolescent Psychopharmacology.
Fan M, Yarema M, Box A, Hume S, Aitchison KJ, Bousman CA. (2021). Identification of high impact gene-drug pairs for pharmacogenetic testing in Alberta, Canada. Pharmacogenetics and Genomics, 31(2): 29-39.
Liu C, Maruf AA, Bousman CA. (2020). Reporting of clozapine-induced gastrointestinal hypomotility and factors associated with fatal outcomes in Canada: A pharmacovigilance database study. Psychiatry Research.
Jessel C, Mostafa S, Potiriadis M, Everall IP, Gunn JM, Bousman CA. (2020). Use of antidepressants with pharmacogenetic prescribing guidelines in a 10-year depression cohort of adult primary care patients. Pharmacogenetics and Genomics
Maruf AA, Fan M, Arnold P, Mueller DJ, Aitchison K, Bousman CA. (2020). Pharmacogenetic testing options relevant to psychiatry in Canada. The Canadian Journal of Psychiatry.
Lacaze P, Ronaldson K, Zhang E, Alfirevic A, Shah H, Newman L, Strahl M, Smith M, Bousman CA, Francis B, Morris AP, Wilson T, Rossello F, Powell D, Vasic V, Sebra R, McNeil J, Pirmohamed M. (2020). Genetic associations with clozapine-induced myocarditis in patients with schizophrenia. Translational Psychiatry, 10, 37.
Hicks J, Bishop J, Gammal R, Sangkuhl K, Bousman CA, Leeder JS, Lerena A, Muller D, Ramsay L, Scott S, Skaar T, Caudle K, Klein T, Gaedigk A. (2019). A call for clear and consistent communications regarding the role of pharmacogenetics in antidepressant pharmacotherapy. Clinical Pharmacology & Therapeutics, 107(1): 50-52.
Lesche D, Mostafa S, Everall I, Pantelis C, Bousman CA. (2019). Impact of CYP1A2, CYP2C19, and CYP2D6 genotype- and phenoconversion-predicted enzyme activity on clozapine exposure and symptom severity. The Pharmacogenomics Journal.
Bousman CA, Zierhut H, Muller D. (2019). Navigating the labyrinth of pharmacogenetic testing: A guide to test selection. Clinical Pharmacology & Therapeutics.
Maruf AA, Greenslade A, Arnold A, Bousman CA. (2019). Antidepressant pharmacogenetics in children and young adults: A systematic review. Journal of Affective Disorders.
Bousman CA. (2019). CYP2D6 testing to guide risperidone and aripiprazole therapy. The Lancet Psychiatry.
Fan M and Bousman CA. (2019). Commercial Pharmacogenetic Tests in Psychiatry: Do they Facilitate the Implementation of Pharmacogenetic Dosing Guidelines? Pharmacopsychiatry
Bousman CA, Al Maruf A, Muller D. (2019). Towards the integration of pharmacogenetics in psychiatry: A minimum, evidence-based genetic testing panel. Current Opinion in Psychiatry.
Bousman CA, Arandjelovic K, Mancuso SG, Eyre H, Dunlop BW. (2018). Pharmacogenetic tests and depressive symptom remission: A meta-analysis of randomized controlled trials. Pharmacogenomics.
Bousman CA and Müller DM. (2018). Pharmacogenetics in Psychiatry: A companion, rather than competitor, to protocol-based care. JAMA Psychiatry , 75(10): 1090
Bousman CA, Eyre H, Allen J. (2018). Pharmacogenetic Tests in Psychiatry. American Journal of Psychiatry, 175(2): 189.
Bousman CA and Dunlop BW. (2018). Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetics-based decision support tools. The Pharmacogenomics Journal, 18(5): 613-622.
Chang D, Eyre H, Abbott R, Coudreaut M, Baune B, Shaman J, Lavretsky H, Lenze E, Merrill D, Singh A, Mulsant B, Reynold C, Muller D, Bousman, CA. (2018). Pharmacogenetic guidelines and decision support tools for depression treatment: Application to late-life. Pharmacogenomics, 19(16): 1269-1284.
Arandjelovic K, Eyre H, Lenze E, Singh AB, Berk M, Bousman CA. (2018). The role of depression pharmacogenetics decision support tools in shared decision making. Journal of Neural Transmission.
Bousman CA, Jaksa P, Pantelis C. (2017). Systematic evaluation of commercial pharmacogenetic testing in psychiatry: A focus on CYP2D6 and CYP2C19 allele coverage and results reporting. Pharmacogenetics and Genomics, 27(11):387-393.
Bousman CA, Forbes M, Jayaram M, Eyre H, Reynolds C, Berk M, Hopwood M, Ng C. (2017). Antidepressant prescribing in the precision medicine era: A prescriber's primer on pharmacogenetic tools. BMC Psychiatry 17(1): 60-67.
Bousman CA, Mueller D, Ng C, Byron K, Berk M, Singh A. (2017). Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: A 10-week open-label study. Pharmacogenetics and Genomics, 27(1) 1-6.
Bousman CA and Hopwood M. (2016). Commercial pharmacogenetic-based decision support tools in psychiatry. The Lancet Psychiatry
Bousman, C.A., Sarris, J., Won, ES., Chang, HS., Singh, A., Lee, HY., Ham, BJ., Tan, CH., Lee, MS., Ng, CH. (2014). Escitalopram efficacy in depression: A cross-ethnicity examination of the serotonin transporter promoter polymorphism. Journal of Clinical Psychopharmacology, 34(5): 645-8.
